Skip to main content

Table 5 Time-varying HR estimatesa from a fixed-effects NMA for DMFS (p1 = 0, p2 = −0.5, scale, shape ×1) in patients with stage II–IV melanoma

From: Comparative efficacy and safety of adjuvant nivolumab versus other treatments in adults with resected melanoma: a systematic literature review and network meta-analysis

Treatment Time points
12 months 24 months 36 months 48 months
NIVO vs. OBS/PBO 0.67 (0.48–0.93) 0.77 (0.50–1.20) 0.83 (0.46–1.49) 0.87 (0.42–1.76)
NIVO vs. DAB+TRAM 1.06 (0.68–1.63) 0.65 (0.37–1.14) 0.51 (0.24–1.07) 0.44 (0.17–1.08)
NIVO vs. IPI (10 mg/kg) 0.80 (0.61–1.06) 0.88 (0.60–1.28) 0.93 (0.55–1.56) 0.96 (0.50–1.84)
NIVO vs. IFN 0.73 (0.51–1.05) 0.80 (0.51–1.27) 0.84 (0.47–1.53) 0.86 (0.42–1.78)
  1. aThe value in each cell represents the hazard ratio (95% credible interval) for the comparison of the treatments; bolded values are statistically significant at the 0.05 significance level
  2. DAB dabrafenib, DMFS distant metastasis-free survival, HR hazard ratio, IFN interferon, IPI ipilimumab, NIVO nivolumab, NMA network meta-analysis, OBS observation, PBO placebo, TRAM trametinib